

## JOHNS HOPKINS HEALTHCARE

7231 Parkway Drive, Suite 100, Hanover, MD 21076

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

## **USFHP Pharmacy Prior Authorization Form**

To be completed by Requesting	provider
Drug Name:	Strength:
Dosage/Frequency (SIG):	Duration of Therapy:

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step	Please complete patient and physician information (please pr	rint):			
1	Patient Name: Physician Name:				
	Address:	Address:			
	Sponsor ID #				
Cton	Date of Birth:	Secure Fax #:			
Step	Please complete the clinical assessment:				
2	<ol> <li>Has the patient received this medication under the TRICARE benefit in the last 6 months? Please choose "No" if the patient did not previously have a TRICARE approved PA for</li> </ol>	☐ Yes (subject to verification)	☐ No Proceed to question 2		
	Palynziq	Proceed to question 8			
	2. Is the patient 18 years of age or older?	☐ Yes	□ No		
		Proceed to question 3	STOP		
			Coverage not approved		
	3. Does the patient have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on at least	☐ Yes	□ No		
	one existing treatment modality (e.g., restriction of	Proceed to question 4	STOP		
	dietary phenylalanine and protein intake, or prior treatment with Kuvan [sapropterin dihydrochloride tablets and powder for oral solution])?		Coverage not approved		
	4. Is the requested medication being prescribed by or in	☐ Yes	□ No		
	consultation with a metabolic disease specialist (or specialist who focuses on the treatment of metabolic	Proceed to question 5	STOP		
	diseases)?		Coverage not approved		
	5. Does the provider acknowledge and has educated the patient on the risk of anaphylaxis?	☐ Yes	□ No		
	patient on the risk of anaphytaxis:	Proceed to question 6	STOP		
			Coverage not approved		
	6. Does the patient have a prescription for self- administered SQ epinephrine?	☐ Yes	□ No		
	aummistereu ou epmepmine?	Proceed to question 7	STOP		
			Coverage not approved		

## Prior Authorization Request Form for pegvaliase-pqpz (**Palynziq**)

7.	7.	7. Is the patient using Palynziq concomitantly with Kuvan?	☐ Yes	□ No
			STOP	Sign and date below
_			Coverage not approved	
	8. Is the patient's blood phenylalanine concentration less than or equal to 600 micromol/L?		□ Yes	□ No
		Proceed to question 10	Proceed to question 9	
	9.	to 20% reduction in blood phenylalanine concentration from pre-treatment baseline (i.e., blood	□ Yes	□ No
			Proceed to question 10	STOP
		phenylalanine concentration before starting Palynziq therapy)?		Coverage not approved
_	10.	). Is the patient using Palynziq concomitantly with Kuvan?	□ Yes	□ No
		TWYWIT.	STOP	Sign and date below
			Coverage not approved	
•	I ce	ertify the above is true to the best of my knowledge. Pleas	se sign and date:	
Step 3	l ce	ertify the above is true to the best of my knowledge. Pleas	se sign and date:	
•	l ce	ertify the above is true to the best of my knowledge. Please	se sign and date:	
•	l ce			[31 July 2019]
•	I ce			[31 July 2019]
•	I ce			[31 July 2019]
3		Prescriber Signature		[31 July 2019]
3				[31 July 2019]
3	al U	Prescriber Signature		
3 r Interna	<b>al U</b>	Prescriber Signature	Date	
r Interna	<b>al U</b>	Prescriber Signature  Use Only	Date  Duration of Approval:	
r Interna Approve	al U	Prescriber Signature  Use Only  /Other:	Duration of Approval: Authorized By:	month(s)